Dalam Ly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2958470/publications.pdf Version: 2024-02-01



DALAMIY

#	Article	IF	CITATIONS
1	Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cellular and Molecular Immunology, 2019, 16, 6-18.	10.5	322
2	Blockade of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Exacerbates Type 1 Diabetes in NOD Mice. Diabetes, 2003, 52, 1967-1975.	0.6	103
3	Bee venom processes human skin lipids for presentation by CD1a. Journal of Experimental Medicine, 2015, 212, 149-163.	8.5	98
4	Protection from Type 1 Diabetes by Invariant NK T Cells Requires the Activity of CD4+CD25+ Regulatory T Cells. Journal of Immunology, 2006, 177, 3695-3704.	0.8	96
5	CD1c tetramers detect ex vivo T cell responses to processed phosphomycoketide antigens. Journal of Experimental Medicine, 2013, 210, 729-741.	8.5	94
6	Interleukin-4 but not Interleukin-10 Protects Against Spontaneous and Recurrent Type 1 Diabetes by Activated CD1d-Restricted Invariant Natural Killer T-Cells. Diabetes, 2004, 53, 1303-1310.	0.6	80
7	Molecular Analysis of Lipid-Reactive Vδ1 γδT Cells Identified by CD1c Tetramers. Journal of Immunology, 2016, 196, 1933-1942.	0.8	72
8	Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms. Clinical Cancer Research, 2018, 24, 370-382.	7.0	57
9	Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by αβ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4648-57.	7.1	49
10	CD1a, CD1b, and CD1c in Immunity Against Mycobacteria. Advances in Experimental Medicine and Biology, 2013, 783, 181-197.	1.6	46
11	NKT Cells Stimulated by Long Fatty Acyl Chain Sulfatides Significantly Reduces the Incidence of Type 1 Diabetes in Nonobese Diabetic Mice. PLoS ONE, 2012, 7, e37771.	2.5	44
12	Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. , 2019, 7, 17.		38
13	The CD1 size problem: lipid antigens, ligands, and scaffolds. Cellular and Molecular Life Sciences, 2014, 71, 3069-3079.	5.4	32
14	Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. Journal of Experimental and Clinical Cancer Research, 2019, 38, 123.	8.6	32
15	CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy. Blood, 2021, 137, 2171-2181.	1.4	23
16	Infusion of <i>ex-vivo</i> expanded human TCR-αβ+ double-negative regulatory T cells delays onset of xenogeneic graft- <i>versus</i> -host disease. Clinical and Experimental Immunology, 2018, 193, 386-399.	2.6	19
17	An α-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes. Clinical and Experimental Immunology, 2010, 160, 185-198.	2.6	17
18	Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Nature Biotechnology, 2021, 39, 958-967.	17.5	15

Dalam Ly

#	Article	IF	CITATIONS
19	Role of Regulatory Invariant CD1d-Restricted Natural Killer T-Cells in Protection Against Type 1 Diabetes. Immunologic Research, 2005, 31, 177-188.	2.9	14
20	Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients. Cancer Immunology Research, 2017, 5, 821-829.	3.4	14
21	Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. ELife, 2020, 9, .	6.0	13
22	Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. Cancers, 2022, 14, 205.	3.7	10
23	The autoimmune regulator (Aire) controls iNKT cell development and maturation. Nature Medicine, 2006, 12, 624-626.	30.7	8
24	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. Cancers, 2019, 11, 1009.	3.7	2
25	NKT Cells and Autoimmune Type 1 Diabetes. , 2005, , 43-53.		0
26	iNKT Cell Regulation of Type 1 Diabetes. Clinical Immunology, 2007, 123, S24.	3.2	0
27	P2.03b-089 CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin. Journal of Thoracic Oncology, 2017, 12, S990.	1.1	0
28	P1.04-02 Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy with PD1 Checkpoint Blockade. Journal of Thoracic Oncology, 2018, 13, S525-S526.	1.1	0
29	Innate Regulatory iNKT Cells. , 2008, , 501-524.		0
30	Abstract A64: Mast cell expressed FcïµR beta subunit (MS4A2) is prognostic in lung adenocarcinoma. , 2017, , .		0